تحميل

Slzii.com يبحث

يبحث (أخبار)
Tangram Therapeutics Announces First Participant Dosed In Phase 1/2 RESTORE-MASH Trial Of TGM-312, A Novel Investigational Rnai Medicine
(MENAFN - GlobeNewsWire - Nasdaq) Phase 1/2 RESTORE-MASH trial will evaluate safety, pharmacokinetics, and pharmacodynamics of TGM-312 in healthy volunteers and MASH patients Initial data ...
2026-03-05 08:16:33

ماذا تفعل؟
0.037140130996704


أخبار
أخبار

آخر الأخبار والعناوين
(MENAFN - GlobeNewsWire - Nasdaq) Phase 1/2 RESTORE-MASH trial will evaluate safety, pharmacokinetics, and pharmacodynamics of TGM-312 in he...
أخبار